Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Overview
Authors
Affiliations
γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they represent attractive effectors for immuno-therapeutic strategies with a better safety profile and a more favorable anti-tumor efficacy in comparison to conventional αβ T cells. Also, remarkable progress has been achieved re-activating exhausted T lymphocytes with inhibitors of co-regulatory receptors e.g., programmed cell death protein 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT) and of the adenosine pathway (CD39, CD73). Regarding γδ T cells, little evidence is available. This study aimed to immunophenotypically characterize γδ T cells from patients with diagnosed acute myeloid leukemia (AML) in comparison to patients with multiple myeloma (MM) and healthy donors (HD). The frequency, differentiation, activation, and exhaustion status of bone marrow- (BM) derived γδ T cells from patients with AML ( = 10) and MM ( = 11) were assessed in comparison to corresponding CD4 and CD8 T cells and peripheral blood- (PB) derived γδ T cells from HDs ( = 16) using multiparameter flow cytometry. BM-infiltrating Vδ1 T cells showed an increased terminally differentiated cell population (TEMRAs) in AML and MM in comparison to HDs with an aberrant subpopulation of CD27CD45RA cells. TIGIT, PD-1, TIM-3, and CD39 were more frequently expressed by γδ T cells in comparison to the corresponding CD4 T cell population, with expression levels that were similar to that on CD8 effector cells in both hematologic malignancies. In comparison to Vδ2 T cells, the increased frequency of PD-1-, TIGIT-, TIM-3, and CD39 cells was specifically observed on Vδ1 T cells and related to the TEMRA Vδ1 population with a significant co-expression of PD-1 and TIM-3 together with TIGIT. Our results revealed that BM-resident γδ T cells in AML and MM express TIGIT, PD-1, TIM-3 and CD39. As effector population for autologous and allogeneic strategies, inhibition of co-inhibitory receptors on especially Vδ1 γδ T cells may lead to re-invigoration that could further increase their cytotoxic potential.
γδ T cells in hematological malignancies: mechanisms and therapeutic strategies.
Chen X, Sun G, Zhu X Blood Sci. 2024; 7(1):e00213.
PMID: 39676818 PMC: 11637750. DOI: 10.1097/BS9.0000000000000213.
Kruger J, Wellbrock J, Witt M, Kruppa N, Muschhammer J, Bokemeyer C Int J Mol Sci. 2024; 25(21).
PMID: 39518969 PMC: 11546357. DOI: 10.3390/ijms252111412.
The therapeutic role of γδT cells in TNBC.
Li W, Zhao X, Ren C, Gao S, Han Q, Lu M Front Immunol. 2024; 15:1420107.
PMID: 38933280 PMC: 11199784. DOI: 10.3389/fimmu.2024.1420107.
Ge J, Yin X, Sun X, Kou L, Xue X, Ma J Discov Oncol. 2024; 15(1):221.
PMID: 38861194 PMC: 11166614. DOI: 10.1007/s12672-024-01072-3.
γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment.
Liu J, Wu M, Yang Y, Wang Z, He S, Tian X J Transl Med. 2024; 22(1):553.
PMID: 38858763 PMC: 11163710. DOI: 10.1186/s12967-024-05327-z.